Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1α, tumour necrosis factor-α and transforming growth factor-β

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 11-12, 2009, Pages 4415-4421

  Jarai, Rudolf ^a,b   Kaun, Christoph ^b   Weiss, Thomas W ^b   Speidl, Walter S ^b   Rychli, Kathrin ^b   Maurer, Gerald ^b   Huber, Kurt ^a   Wojta, Johann ^a,c  

^a Department of Cardiology and Emergency Medicine ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

B type natriuretic peptides; Human adult cardiac fibroblasts; Pro inflammatory cytokines; Statins

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FLUINDOSTATIN; INDOLE DERIVATIVE; INTERLEUKIN 11; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; MONOUNSATURATED FATTY ACID; ONCOSTATIN M; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECT; FIBROBLAST; GENETICS; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; METABOLISM; UPREGULATION;

ADULT; FATTY ACIDS, MONOUNSATURATED; FIBROBLASTS; HUMANS; INDOLES; INTERLEUKIN-11; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; ONCOSTATIN M; PEPTIDE FRAGMENTS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 77951195849     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00704.x     Document Type: Article

References (33)

1. Jarai R, Wojta J, Huber K. Circulating B-type natriuretic peptides in patients with acute coronary syndromes. Pathophysiological, prognostical and therapeutical considerations. Thromb Haemost. 2005, 94:926-32.
2. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004, 6:257-60.
3. Tsuruda T, Boerrigter G, Huntley BK. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002, 91:1127-34.
4. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002, 91:1103-13.
5. Bradham WS, Moe G, Wendt KA. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002, 282:H1288-95.
6. Oral H, Sivasubramanian N, Dyke DB. Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation. Circulation. 2003, 107:831-7.
7. Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci. 2006, 63:2584-96.
8. Chen D, Assad-Kottner C, Orrego C. Cytokines and acute heart failure. Crit Care Med. 2008, 36:S9-16.
9. Wiesbauer F, Kaun C, Zorn G. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol. 2002, 135:284-92.
10. Weiss TW, Kvakan H, Kaun C. The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart. J Mol Cell Cardiol. 2005, 39:545-51.
11. Weiss TW, Speidl WS, Kaun C. Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res. 2003, 59:628-38.
12. Kapoun AM, Liang F, O'Young G. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004, 94:453-61.
13. Harada E, Nakagawa O, Yoshimura M. Effect of interleukin-1 beta on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. J Mol Cell Cardiol. 1999, 31:1997-2006.
14. Node K, Fujita M, Kitakaze M. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003, 108:839-43.
15. Khush KK, Waters DD, Bittner V. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) Study. Circulation. 2007, 115:576-83.
16. Smit JW, Wijnne HJ, Schobben F. Effects of alcohol and fluvastatin on lipid metabolism and hepatic function. Ann Intern Med. 1995, 122:678-80.
17. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res. 2005, 97:1232-5.
18. Shiga N, Hirano K, Hirano M. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ Res. 2005, 96:1014-21.
19. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998, 273:24266-71.
20. Degraeve F, Bolla M, Blaie S. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem. 2001, 276:46849-55.
21. He Q, LaPointe MC. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension. 1999, 33:283-9.
22. Tanimoto A, Murata Y, Wang KY. Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells. J Biol Chem. 2008, 283:4643-51.
23. Wang TN, Ge YK, Li JY. B-type natriuretic peptide enhances mild hypoxia-induced apoptotic cell death in cardiomyocytes. Biol Pharm Bull. 2007, 30:1084-90.
24. Kogler H, Schott P, Toischer K. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase expression. Circulation. 2006, 113:2724-32.
25. Zhang Q, Moalem J, Tse J. Effects of natriuretic peptides on ventricular myocyte contraction and role of cyclic GMP signaling. Eur J Pharmacol. 2005, 510:209-15.
26. Goukassian DA, Qin G, Dolan C. Tumor necrosis factor-alpha receptor p75 is required in ischemia-induced neovascularization. Circulation. 2007, 115:752-62.
27. Vellaichamy E, Kaur K, Pandey KN. Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. Peptides. 2007, 28:893-9.
28. Kawakami R, Saito Y, Kishimoto I. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation. 2004, 110:3306-12.
29. Dejam A, Hunter CJ, Tremonti C. Nitrite infusion in humans and nonhuman primates. Endocrine effects, pharmacokinetics, and tolerance formation. Circulation. 2007, 116:1821-31.
30. Erusalimsky JD, Moncada S. Nitric oxide and mitochondrial signaling. From physiology to pathophysiology. Arterioscler Thromb Vasc Biol. 2007, 27:2524-31.
31. Cosby K, Partovi KS, Crawford JH. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003, 9:1498-505.
32. van der Zander K, Houben AJ, Kroon AA. Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. J Hypertens. 2002, 20:493-9.
33. Gissi-HFI Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008, 372:1231-9.